BioSpace News Archive

Kisqali is now the only CDK4/6 inhibitor indicated in combination with an aromatase inhibitor as first-line treatment for pre-, peri- or postmenopausal women with HR+/HER2- advanced breast cancer in the US[1]

CareSpeak’s automated patient engagement platform extended days on therapy for Avella patients with cancer by 73 days and with inflammatory disease by 102 days

BSA LifeStructures (BSA) has hired Theresa (Teri) L. Joy, BSN, CEN, TCRN, RN, as senior healthcare operations planner.

Quantapore Inc. announced the completion of a $15.55 million sale of Series 3 Preferred Stock led by Northern Light Venture Capital (NLVC).

DermTech, Inc. announced the publication of “Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions,” by Dr. Laura Ferris of the University of Pittsburgh, et al, in Melanoma Research.

Vapotherm Inc. today announced the publication of a key prospective, multi-center randomized controlled trial. The study demonstrates the non-inferiority of High Velocity Nasal Insufflation (HVNI) to traditional Non-invasive Positive Pressure Ventilation (NiPPV) in the treatment of adult patients with undifferentiated respiratory distress presenting in the Emergency Department. The study included 204 patients and was conducted at five U.S.

Having a voice at the Cabinet table key to addressing Canada’s aging population

Lantheus Holdings, Inc. announced that it will host a conference call at 4:30 p.m. ET on Wednesday, August 1, 2018, to discuss its financial and operating results for the second quarter of 2018.

Board and Management Continue to Take Action to Improve Internal Practices

The U.S. Anti-Doping Agency (USADA) announced today that former UFC Middleweight Champion Anderson Silva’s positive test for banned substances in October 2017 was a result of contaminated supplements purchased from a Brazilian compounding pharmacy, not intentional doping.